AI Article Synopsis

  • A national registry analysis was conducted to evaluate the impact of different surgical treatments on the survival of patients with gastric adenocarcinoma and liver-only metastases.
  • Out of the 10,977 patients studied, those who received both primary tumor resection and liver metastasectomy had the longest median overall survival (OS) of 18.6 months compared to 6.5 months for those with no surgery.
  • The results indicate that for selected patients with favorable conditions, surgical intervention may improve survival outcomes significantly compared to not receiving surgery or undergoing single treatment options.

Article Abstract

Background: The role of metastasectomy in patients with liver-only metastases from gastric adenocarcinoma remains under investigation. Therefore, we performed a national registry analysis comparing surgical treatment options for patients with gastric adenocarcinoma and liver-only metastases.

Patients And Methods: In this retrospective National Cancer Database (2010-2019) study, adults (≥ 18 years) with gastric adenocarcinoma and liver-only metastases (no brain, bone, or lung metastases) were included. Patients were stratified into four groups: no surgical treatment, primary tumor resection (PTR), liver metastasectomy, and PTR with liver metastasectomy. Survival was evaluated using the Kaplan-Meier method, log-rank test, and Cox regression.

Results: Of 10,977 included patients, 93.6% underwent no surgical treatment, 4.6% PTR alone, 0.8% liver metastasectomy alone, and 1.0% both PTR and liver metastasectomy. The median OS after no surgical treatment was 6.5 months, after PTR alone 10.9 months, after liver metastasectomy alone 9.9 months, and after PTR and liver metastasectomy 18.6 months. In multivariable analysis, when adjusting for age, sex, race/ethnicity, insurance status, Charlson-Deyo score, chemotherapy, and radiation, PTR and liver metastasectomy was associated with superior OS compared with no surgical treatment (HR 2.17, 95% CI 1.76-2.69, p < 0.001), PTR alone (HR 1.42, 95% CI 1.12-1.79, p = 0.003), and liver metastasectomy alone (HR 1.96, 95% CI 1.45-2.64, p < 0.001).

Conclusions: These data suggest that, in highly selected patients with gastric adenocarcinoma and synchronous liver-only metastases and favorable biology, surgical resection might grant a survival advantage.

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-024-16318-1DOI Listing

Publication Analysis

Top Keywords

liver metastasectomy
32
gastric adenocarcinoma
20
surgical treatment
20
ptr liver
20
liver-only metastases
16
metastasectomy
9
role metastasectomy
8
metastasectomy patients
8
patients liver-only
8
metastases gastric
8

Similar Publications

Background: Metastasectomy is a useful adjunct in the management of metastatic cancer. Widespread adoption of novel targeted and immunotherapies has improved the survival profiles of multiple malignancies, which has potentially altered the role of metastasectomy. This study aimed to characterize trends in metastasectomy across five primary cancers eligible for these therapies.

View Article and Find Full Text PDF
Article Synopsis
  • * In Cohort A (colorectal cancer), the objective response rate (ORR) was 40.4% with a median progression-free survival (PFS) of 8.7 months, while in Cohort C (non-colorectal/non-esophageal GI cancer), the ORR was 31.8% with a PFS of 5.8 months.
  • * The study indicated promising antitumor activity, enabling liver metastasectomy in some patients, without introducing new safety issues.
View Article and Find Full Text PDF

Introduction: Pancreatic cancer is one of the most aggressive tumors diagnosed in local-ly advanced or metastatic stage in more than half of the cases. The standard of care is a systemic chemotherapy but the prognosis of metastatic patients remains extremely poor with a median overall survival less than one year.  However, there is increasing evidence of surgery treatment benefit in a carefully selected oligometastatic cases.

View Article and Find Full Text PDF

Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial.

Eur J Cancer

January 2025

Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address:

Background: Hepatic artery infusion (HAI) chemotherapy, particularly with floxuridine (FUDR), has previously shown effectiveness in improving recurrence-free survival (RFS) in colorectal cancer (CRC) patients with colorectal liver metastases (CRLM). Nonetheless, its adjuvant use alongside modern systemic chemotherapy remains unevaluated.

Patients And Methods: The HARVEST trial is an open-label, randomized, controlled study conducted from May 2018 to August 2021.

View Article and Find Full Text PDF

Background And Objectives: Multiple primary malignant tumors represent a small percentage of the total number of oncological cases and can involve either metachronous or synchronous development and represent challenges in diagnosis, staging, and treatment planning. Our purpose is to present a rare case of bladder adenocarcinoma in a female patient with multiple primary malignant tumors and to provide systematic review of the available literature.

Materials And Methods: A 67-year-old female patient was admitted with altered general condition and anuria.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!